ReviewBiologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: Systematic literature review and analysis of a monocentric cohort
Introduction
Biologic drugs are licensed for the treatment of chronic inflammatory rheumatic diseases (IRD) including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS). The introduction of anti-TNF-alpha agents has changed the treatment of these inflammatory conditions [1], [2]. Afterwards, a better understanding of disease pathogenesis has led to the development of new-targeted biologic treatments for RA with different mechanisms of action. They act by inhibiting the effect of specific cytokines (IL1, IL6) or selectively targeting CD20-positive B cells or preventing antigen-presenting cells from delivering the co-stimulatory signal to T lymphocytes by binding to CD80 and CD86, thereby blocking interaction with CD28 [3]. Further treatment modalities are being investigated such as targeting IL-17 to modulate Th17/Treg balance and reduce inflammation [4].
Biologics are usually considered cost-effective in controlling disease activity, inhibiting the progression of structural damage and reduce the risk of co-morbidities such as osteoporosis in patients with chronic IRD [5], [6], [7]. On the other hand, all of these drugs have a range of shared adverse effects including the paradoxical development of autoimmune processes, ranging from asymptomatic immunologic alterations to life-threatening systemic autoimmune diseases [8]. The higher number of reports on the development of autoimmunity is related to the use of TNF-alpha-blocking agents, however other biologics have recently been associated with the development of systemic and organ specific autoimmune conditions [9]. Although unusual, biologics-induced autoimmune kidney damage has been reported in patients affected by chronic IRD as isolated disorder or as part of the spectrum of drug-induced Systemic Lupus Erythematosus (SLE) and drug-induced systemic vasculitis [8], [9]. However, the clinical characteristics and outcomes of autoimmune renal disorders (AIRD) triggered by biological therapy have not been specifically addressed. The purpose of this study is to describe the features of biologics-induced AIRD in adult patients with chronic IRD through a systematic review and the analysis of a monocentric cohort followed-up in an Italian third level center of rheumatology.
Section snippets
Systematic review
Two investigators (MP, EC) performed a systematic review of the literature, according to the PRISMA guidelines, searching for articles published between the 1st of January 1990 and the 31st of January 2014 reporting on the development of AIRD (Outcome) in adult patients with IRD (Population) receiving biologics (Intervention). The following search strategy through MEDLINE via PubMed was designed using a combination of Mesh terms: (“Arthritis, Rheumatoid”[Mesh]) OR (“Spondylitis,
Literature search
The literature search identified 2687 articles, from which 24 were initially considered relevant for the present study. The manual search retrieved 7 additional articles. Finally, 21 articles were included in the study (Fig. 1), accounting for 26 case reports. Reasons for exclusion were especially diseases of interest different from IRD and treatment different from biologics. Among the articles retrieved by PubMed search 8 were excluded because they did not report of descriptive features of
Discussion
Despite mesangial GN, membranous GN and minimal change nephropathy have been described as extra-articular manifestations of IRD, mainly in RA and rarely in AS and PsA, glomerular disease in these patients is more commonly related to secondary amyloidosis or complications of drug therapy [31]. Lupus nephritis may very rarely develop in a subset of RA patients who have overlap with SLE [32], while ANCA positivity in RA has been related to the development of NCGN [33]. Drug-induced nephropathy is
Take-home message
- •
Biologics-induced AIRD are mostly, but not exclusively, associated with anti-TNF-alpha treatment.
- •
Although rare, AIRD may be life-threatening and may lead to renal failure and death.
- •
If AIRD occur the biologic drug must be stopped.
- •
Treatment of AIRD should be tailored to clinical manifestations and kidney biopsy findings.
Acknowledgment
Matteo Piga gratefully acknowledges the Sardinian Regional Government for its financial support (P.O.R. Sardegna F.S.E. Operational Program of the Autonomous Region of Sardinia, European Social Fund 2007–2013 — Axis IV Human Resources, Objective l.3, Line of Activity l.3.1).
References (46)
- et al.
Th17 and regulatory T cell balance in autoimmune and inflammatory diseases
Autoimmun Rev
(2014) - et al.
Biologic therapies and systemic bone loss in rheumatoid arthritis
Autoimmun Rev
(2013) - et al.
Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?
Autoimmun Rev
(2013) Novel diagnostic approaches and cost–benefit balance of treatment of immune-mediated and rare disease in the era of biologic drugs: lessons from the 15th Turin Congress on Immune Pathology and Orphan Disease
Autoimmun Rev
(2013)- et al.
Autoimmune diseases induced by biological agents: a double-edged sword?
Autoimmun Rev
(2010) - et al.
Mesangial immunoglobulin (Ig)A glomerulonephritis in a patient with rheumatoid arthritis treated with abatacept
Joint Bone Spine
(2013) - et al.
Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab
Am J Kidney Dis
(2010) - et al.
ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy
Am J Kidney Dis
(2008) - et al.
Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis
Joint Bone Spine
(2004) - et al.
Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France
Joint Bone Spine
(2006)
Drug-induced lupus due to anti-tumor necrosis factor alpha agents
Semin Arthritis Rheum
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
Ann Rheum Dis
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
Ann Rheum Dis
Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis
Biogeosciences
Biologics-induced autoimmune diseases
Curr Opin Rheumatol
Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis
Mod Rheumatol
Membranous glomerulonephritis with the use of etanercept in ankylosing spondylitis
Ann Pharmacother
Membranous nephropathy in rheumatoid arthritis: a case report
Clin Exp Rheumatol
Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis
Nephrol Dial Transplant
Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis
Neth J Med
IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy
Nephrol Dial Transplant
Tocilizumab-induced immune complex glomerulonephritis in a patient with rheumatoid arthritis
Rheumatology (Oxford)
Tumor necrosis factor-alpha inhibitor-induced antiglomerular basement membrane antibody disease in a patient with rheumatoid arthritis
J Rheumatol
Cited by (69)
Rheumatoid arthritis: Extra-articular manifestations and comorbidities
2021, Autoimmunity ReviewsCitation Excerpt :Since the first report of 2 RA patients treated with anti-TNF alpha developed glomerulonephritis by Kemp et al. [89], several additional cases of paradoxical autoimmune renal involvement after biologic therapy have been reported. Autoimmune renal disorders induced by biologics is rare, reported in 0.9 cases per 1000 patient-years, but clinicians should be aware of this potentially life-threatening event [90]. Studies support that RA has a modestly higher overall incidence of malignancy compared to the general population [91].
Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor
2021, Kidney MedicineCitation Excerpt :More recently, anti–tumor necrotic factor α therapies have been added to this list. Multiple cases of biologic-induced autoimmune kidney disorders were recently reported.2 This includes glomerulonephritis associated with systemic vasculitis, glomerulonephritis in lupus-like syndrome, and isolated autoimmune kidney disorders.
Crohn's Disease With Progressive Renal Impairment
2020, GastroenterologyInfliximab biosimilar-induced lupus nephritis: A case report
2024, Modern Rheumatology Case Reports